Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05211375

Comparisons of Metabolic Effect of Sleeve Gastrectomy With Duodenojejunal Bypass and Sleeve Gastrectomy (MEDUSA): A Multicenter Randomized Controlled Trial

In this study, the effects of SG with DJB and SG alone for the treatment of type 2 diabetes mellitus (T2DM) will be compared in patients other than the two groups at both extremes who are expected to show excellent effects of metabolic surgery with SG alone (mild T2DM) and who need SG with DJB (severe T2DM).

This study is to target patients with poor blood sugar control despite current medical treatment, although the beta-cell function of the pancreas is preserved. Therefore, this study is aimed at patients who have been using insulin for less than 10 years with T2DM, or taking diabetic medications with HbA1c ≥ 7.0% for less than 10 years with T2DM.

The investigators hypothesize that the treatment effects of SG with DJB for T2DM will be superior to that of SG in this group

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Seoul National University Bundang Hospital

Seongnam-si, 13620, South Korea

Location status: Recruiting

Location contact

Young Suk Park

CONTACT

[email protected]

About this study

Most Asian patients undergoing metabolic surgery for the treatment of T2DM have BMI as low as 30-35 kg/m2. If SG is performed for the treatment of T2DM in these patients, weight may decrease after the surgery; however, T2DM may recur after 6 months to 1 year. Therefore, it is difficult to find clinical studies on SG for metabolic surgery in Asians, and gastric bypass may be more appropriate as metabolic surgery. However, gastroscopy for the remnant stomach after gastric bypass is practically impossible. Therefore, gastric bypass may be a fatal drawback for East Asian patients with a high incidence of gastric cancer. In recent years, modified duodenal switch (SG with duodenojejunal bypass [DJB], which is defined as the procedure that makes jejunal bypass shorter than the traditional duodenal switch) is often performed as metabolic surgery, and studies on this surgical technique are being actively conducted in Japan.

SG with DJB has both effects of stomach restriction and foregut bypass. However, SG with DJB is more disadvantageous compared to SG alone in nutrient absorption after surgery. This is a natural result of bypassing the duodenum and proximal jejunum. Therefore, SG with DJB should not be performed when it is unnecessary, and it should be performed in patients who are expected to show significant improvement in T2DM. However, there is no existing guideline on which patients can receive SG with DJB or SG alone, and there are also no clinical studies on these aspects.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age over 18 years
  • BMI equal to or greater than 27.5 kg/m2
  • T2DM duration ≤ 10 years
  • Using insulin, or HbA1c ≥ 7.0% while taking diabetes medication
  • C-peptide level higher than 1.0 ng/mL
  • Presence of type 2 diabetes fulfilling the following criteria
  • Consent to not become pregnant for at least 1 year after surgery
  • Willingness to provide voluntary informed consent

Exclusion criteria

  • Presence of uncontrolled severe gastroesophageal reflux (LA classification C or more in esophagogastroduodenoscopy)
  • History of previous metabolic surgery for T2DM
  • History of gastrointestinal surgery, such as gastrectomy or anti-reflux surgery, which may affect the result of metabolic surgery
  • Therapy regimen of more than 3 psychiatric drugs owing to poorly controlled psychiatric disorders
  • Suicidal attempts within the last 12 months
  • Treatment for alcohol and drug abuse within the last 12 months
  • Vulnerability factors (lacking mental capacity, pregnancy or planning of pregnancy, lactation)
  • Unsuitability as per the discretion of the researcher

Treatment and study plan

Duodenojejunal bypass

Procedure

Sleeve gastrectomy will be performed in the same manner as in the SG group. DJB will be performed by transection of the duodenum and bypassing 250 cm of the proximal jejunum. The handsewn suture will be used for duodenojejunal anastomosis, and the size of anastomosis will be 1.5 - 2 cm. Single anastomosis will be performed rather than Roux-en-Y fashion.

Sleeve gastrectomy

Procedure

Sleeve gastrectomy will be performed using 36-38 Fr bougie. The initial stapling start point will be between 4-6 cm from the pylorus, and the last stapling will be performed at least 1 cm away from His angle. The height of the automatic stapler will be selected based on the researcher's discretion.

Primary outcomes

  1. Complete remission rate of type 2 diabetes

    Time frame: 5 years after surgery

    HbA1c <6% (or fasting blood glucose [FBG] <100 mg/dL) without using any diabetes medication

Secondary outcomes

  1. Complete remission rate of type 2 diabetes

    Time frame: 1, 3, 10 years after surgery

    HbA1c <6% (or fasting blood glucose [FBG] <100 mg/dL) without using any diabetes medication

  2. Partial remission rate of type 2 diabetes

    Time frame: 1, 3, 5, 10 years after surgery

    Definition of partial remission of diabetes: HbA1c of 6-6.4% (or FBG of 100-125 mg/dL) without using any diabetes medication

  3. Improvement rate of type 2 diabetes

    Time frame: 1, 3, 5, 10 years after surgery

    Definition of improvement of diabetes: Significant reduction in HbA1c (or FBG) level or decrease in the number of diabetic drugs or stoppage of insulin that does not meet the definition of remission.

  4. Hypertension remission rate

    Time frame: 1, 3, 5, 10 years after surgery

    Definition of complete remission of hypertension: Blood pressure (BP) <120/80 mmHg without taking BP medication Definition of partial remission of hypertension: BP of 120-140/80-89 mmHg without taking BP medication

  5. Hypertension improvement rate

    Time frame: 1, 3, 5, 10 years after surgery

    Definition of improvement of hypertension: Decrease in the number or dose of BP medications or decreased BP while taking medication

  6. Hyperlipidemia remission rate

    Time frame: 1, 3, 5, 10 years after surgery

    Definition of remission of hyperlipidemia: Normal lipid profile (triglyceride [TG] <150 mg/dL and low-density lipoprotein [LDL] of 129 mg/dL or less and high-density lipoprotein [HDL] of 40 mg/dL or above) without taking hyperlipidemic drugs

  7. Hyperlipidemia improvement rate

    Time frame: 1, 3, 5, 10 years after surgery

    Definition of improvement of hyperlipidemia: Reduced number or dose of hyperlipidemic drugs or improved lipid profile while taking hyperlipidemic drugs

  8. Prevalence of GERD

    Time frame: 1, 3, 5, 10 years after surgery

    Acid reflux symptoms and positive endoscopic findings (LA classification A or more)

  9. Trace element deficiency rate (iron, vitamin B12, folate, vitamin B1, vitamin D, copper [Cu], and zinc [Zn])

    Time frame: 1, 3, 5, 10 years after surgery

    Iron deficiency: ferritin <20 ng/mL or iron <50 mcg/dL Vitamin B12 deficiency: <200 pg/mL, vitamin B12 suboptimal: 200 - <400 pg/mL Folate deficiency: <10nmol/L (4.4ng/mL) Vitamin B1 deficiency: <2.36 mcg/dL Vitamin D deficiency: <20 mg/mL, vitamin D insufficiency: 20-<30 ng/mL Cu deficiency: <75 mcg/dL Zn deficiency: <70 mcg/dL in women, < 74 mcg/dL in men

  10. Changes in body weight

    Time frame: 1, 3, 5, 10 years after surgery

    kilograms

  11. Changes in body composition

    Time frame: 1, 3, 5, 10 years after surgery

    body fat percentage(%), body fat mass (kg), and muscle mass(kg)

  12. Changes in Quality of life

    Time frame: 1, 3, 5, 10 years after surgery

    IWQOL-Lite, SF-12

  13. Early complication rate

    Time frame: Early: within 30 days after surgery

  14. Late complication rate

    Time frame: Late: later than 30 days after surgery

Study contacts

Contact information is provided by the study sponsor or research team.

Young Suk Park

CONTACT

[email protected]

+82-10-8980-6094

Sponsors and collaborators

Lead sponsor

Seoul National University Bundang Hospital

Other

Collaborators

  • Ajou University School of Medicine
  • Ewha Womans University Seoul Hospital
  • Korea University
  • Seoul Metropolitan Boramae Hospital
  • Soonchunhyang University Hospital
  • The Catholic University of Korea
  • The Catholic University of Korea Eunpyeong St. Mary's Hospital

Registry information

Important dates

Study start
2022
Primary completion
2031
Study completion
2036
First posted
Jan 27, 2022
Registry last updated
Jan 27, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.